A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral HRS5685 in Healthy Subjects

NCT05328583 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

64

Enrollment

INDUSTRY

Sponsor class

Conditions

Human Immunodeficiency Virus-1 (HIV-1) Infection

Interventions

DRUG: HRS5685；Placebo

Sponsor

RetroLead (Shanghai) BioPharma Co., Ltd.